Skip to content
FDA Import Alert · 66-40

Guangxi Yulin Pharmaceutical Group Co. Ltd. · Yulin, CHINA

Listed 2025-09-26 · 15 product codes · Source: FDA Import Alert 66-40 · View on FDA

A facility listed under this company name on the FDA Import Alert list as checked on 2026-11-09. See the FDA page for the listed address and products. Full Import Alert list

Firm Record

Guangxi Yulin Pharmaceutical Group Co. Ltd.

10 findings from 2 inspection documents published by regulators. Each row below says what its date means.

US FDA · 2025-10-21 ~ 2026-11-13

Areas cited

Laboratory and QC controlsStability and storageProcess validationEquipment and facilityComputer system validationLabeling and packaging

Published inspection documents

Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)). Your firm failed to adequately determine the appropriate laboratory testing necessary for your (b)(4) over the counter (OTC) drug products. For example, you did not perform testing for identity and strength of the active ingredients prior to drug product release and distribution. This is a repeat observation from the 2016 inspection. In your response, you indicate your intent to conduct active ingredient testing for retain samples of batches that have been distributed to the United States and to develop a risk assessment. However, your response is inadequate because you do not propose a comprehensive corrective action and preventive action plan to ensure that appropriate testing is conducted prior to drug product release. In addition, you do not indicate further actions that your firm will pursue for distributed drug products if test results are found to be outside specification. Full release testing, including strength and identity testing of the active ingredients, must be performed before drug product release and distribution. Without adequate testing, you do not have adequate scientific evidence to ensure that your drug products conform to appropriate specifications before their release. 2025-10-21 US FDA 4 findingsLaboratory and QC controls · Computer system validation and 1 more View the regulator's official source

Other companies with similar findings

Other companies with findings worded closely to this company's. Only documents of the same type are compared.

A record as of publication. Check the agency's own announcements for any later corrective action.

What is included. As collected on 2026-11-15: only documents with a detail page (3 or more findings). See the firm lookup for everything.

Full history of Guangxi Yulin Pharmaceutical Group Co. Ltd. — including inspection classifications Browse by document Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.